cCTL(Obstetrics and Gynecology Hospital of Fudan University) in Female Genital Neoplasms: NCT07434284 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Early Phase 1
Clinical phase
Recruiting
Recruitment status
20
Planned enrollment
2027-12-01
Primary-completion proxy
Executive view
NCT07434284 evaluates cCTL(Obstetrics and Gynecology Hospital of Fudan University) in Female Genital Neoplasms. The disclosed sponsor is Obstetrics and Gynecology Hospital of Fudan University, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Objective response rate (ORR), assessed over From enrollment to the end of treatment at 8 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07434284 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Female Genital Neoplasms landscape. Drug & Asset MCP drug_fetch was queried for cCTL(Obstetrics and Gynecology Hospital of Fudan University), while Company & Deal Intelligence MCP organization_fetch was queried for Obstetrics and Gynecology Hospital of Fudan University.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07434284 | cCTL(Obstetrics and Gynecology Hospital of Fudan University) | Early Phase 1 / Recruiting | Obstetrics and Gynecology Hospital of Fudan University | China | Objective response rate (ORR) From enrollment to the end of treatment at 8 weeks | 2027-12-01 |
| NCT07470853 | HWK-016 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles) | 2028-02-01 |
| NCT07462663 | GLP-1 agonist (Nxera Pharma) | Phase 4 / Not yet recruiting | Bellvitge University Hospital | Geography not reported | Recruitment Rate From study opening to end of recruitment, up to 36 months. | 2031-04-01 |
| NCT07453394 | Olaparib | Phase 1/2 / Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Geography not reported | Incidence and severity of adverse events up to 2 years | 2027-04-01 |
| NCT07444814 | HWK-007 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles) | 2028-10-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07434284 is a Early Phase 1, recruiting study with 20 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Objective response rate (ORR)” over “From enrollment to the end of treatment at 8 weeks.” The retrieved endpoint description is: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR). ORR was defined as the percentage of participants who had a Complete Response (Disappearance of all target lesions) or a Partial Response (≥30% decrease in the sum of the longest diameter of target lesions) using RECIST 1.1 based on BICR..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 20 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Female Genital Neoplasms. These records do not establish direct evidence for NCT07434284 unless the registration number matches.
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…
Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given…
Phase 1/2; n=19; Number of Participants With DLTs in Each Module = 0 Participants ; Number of Participants With DLTs in Each Module = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05714553
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
cCTL(Obstetrics and Gynecology Hospital of Fudan University) is indexed as T-lymphocyte cell therapy with target not reported biology and a global stage of Early Phase 1. The asset profile lists Obstetrics and Gynecology Hospital of Fudan University as an originator or developer.
Obstetrics and Gynecology Hospital of Fudan University is indexed in China with the website http://www.fckyy.org.cn. The organization record is used to resolve sponsor identity. The record lists 3 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether cCTL(Obstetrics and Gynecology Hospital of Fudan University) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07434284
Protocol source: https://clinicaltrials.gov/study/NCT07434284
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
cCTL(Obstetrics and Gynecology Hospital of Fudan University) in Female Genital Neoplasms is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Objective response rate (ORR) and 2027-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
